NCT04483973View on ClinicalTrials.gov

SPI-1005 Treatment in Severe COVID-19 Patients

PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 27, 2021

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Covid19CoronavirusCoronavirus InfectionCorona Virus Infection
Interventions
DRUG

Ebselen

Glutathione peroxidase mimetic

DRUG

Placebo

Matching placebo containing excipients

Trial Locations (7)

27109

Wake Forest University, Winston-Salem

27710

Duke University, Durham

63130

Washington University in St. Louis, St Louis

66160

Kansas University Medical Center, Kansas City

75390

University of Texas Southwestern, Dallas

83702

St. Luke's Cystic Fibrosis Center of Idaho, Boise

96510

Yale University, New Haven

All Listed Sponsors
lead

Sound Pharmaceuticals, Incorporated

INDUSTRY